Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 20/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2431429 | 1.00 | REN (0.53) | REN | |
| SCHEMBL15202901 | 0.90 | REN (0.44) | REN | |
| SCHEMBL9978449 | 0.89 | REN (0.56) | REN | |
| SCHEMBL4456027 | 0.89 | REN (0.54) | REN | |
| SCHEMBL9978514 | 0.89 | REN (0.54) | REN | |
| SCHEMBL9978382 | 0.89 | REN (0.58) | REN | |
| SCHEMBL9978447 | 0.89 | REN (0.56) | REN | |
| SCHEMBL4456020 | 0.89 | REN (0.54) | REN | |
| SCHEMBL9978743 | 0.89 | REN (0.56) | REN | |
| SCHEMBL9978360 | 0.89 | REN (0.54) | REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011148392-A1 | PROCESS FOR THE PREPARATION OF (2S,4S,5S,7S)-N-(2-CARBAMYL-2- METHYLPROPYL)-5-AMINO-4-HYDROXY-2,7-DIISOPROPYL-8-[4-METHOXY-3-(3- METHOXYPROPOXY)PHENYL]-OCTANAMIDE HEMIFUMARATE AND ITS INTERMEDIATES THEREOF | MSN LABORATORIES LIMITED (IN) | 2011-12-01 | — | — | WO | claimed |
| EP-2814806-B1 | AN IMPROVED PROCESS FOR THE PREPARATION OF ALISKIREN | MYLAN LAB LTD (IN) | 2016-05-25 | — | — | EP | disclosed |
| US-9090537-B2 | Process for the preparation of aliskiren | MYLAN LABORATORIES LIMITED (IN) | 2015-07-28 | — | — | US | disclosed |
| US-9090537-B2 | Process for the preparation of aliskiren | MYLAN LABORATORIES LIMITED (IN) | 2015-07-28 | — | — | US | disclosed |
| US-20150011793-A1 | PROCESS FOR THE PREPARATION OF ALISKIREN | MYLAN LABORATORIES LTD (IN) | 2015-01-08 | — | — | US | disclosed |
| US-20150011793-A1 | PROCESS FOR THE PREPARATION OF ALISKIREN | MYLAN LABORATORIES LTD (IN) | 2015-01-08 | — | — | US | disclosed |
| WO-2013121443-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF ALISKIREN | Mylan Laboratories Ltd. (IN) | 2013-08-22 | — | — | WO | disclosed |
| WO-2013118138-A1 | NOVEL PROCESS FOR THE PREPARATION OF RENIN INHIBITORS | MYLAN LABORATORIES LTD (IN) | 2013-08-15 | — | — | WO | disclosed |
| WO-2011148392-A1 | PROCESS FOR THE PREPARATION OF (2S,4S,5S,7S)-N-(2-CARBAMYL-2- METHYLPROPYL)-5-AMINO-4-HYDROXY-2,7-DIISOPROPYL-8-[4-METHOXY-3-(3- METHOXYPROPOXY)PHENYL]-OCTANAMIDE HEMIFUMARATE AND ITS INTERMEDIATES THEREOF | MSN LABORATORIES LIMITED (IN) | 2011-12-01 | — | — | WO | disclosed |
| EP-2364292-A2 | AMIDE INHIBITORS OF RENIN | Auspex Pharmaceuticals, Inc. (US) | 2011-09-14 | — | — | EP | disclosed |
| WO-2010059967-A2 | AMIDE INHIBITORS OF RENIN | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-05-27 | — | — | WO | disclosed |
| WO-2010059967-A2 | AMIDE INHIBITORS OF RENIN | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-05-27 | — | — | WO | disclosed |
| US-20100124550-A1 | AMIDE INHIBITORS OF RENIN | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-05-20 | — | — | US | disclosed |
| US-20100124550-A1 | AMIDE INHIBITORS OF RENIN | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-05-20 | — | — | US | disclosed |
| US-20100124550-A1 | AMIDE INHIBITORS OF RENIN | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100124550-A1 | AMIDE INHIBITORS OF RENIN | REN, ACE, AGTR2 | REN 1/4885 |
| US-20150011793-A1 | PROCESS FOR THE PREPARATION OF ALISKIREN | AGTR2, REN, AGTR1 | REN 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.